Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:16:58.229Z.
Calculation as of: 2026-10-06T14:16:58.229Z.
Quote observation: 2026-10-06T14:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$56.29M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $58.57M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.84M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $58.80M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.31M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.64M | N/A | 98.33 | 98.33 | 98.33 |
| Spectral AI, Inc. (MDAI)vs › | $56.65M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $55.97M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.29M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.57 | 6.78 | 6.78 | 131.43 |
| Apollomics, Inc. (APLM)vs › | $53.17M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
